Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Income from Continuing Operations (2016 - 2025)

Neurocrine Biosciences' Income from Continuing Operations history spans 16 years, with the latest figure at 153700000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 49.08% year-over-year to 153700000.0; the TTM value through Dec 2025 reached 478600000.0, up 40.23%, while the annual FY2025 figure was 478600000.0, 40.23% up from the prior year.
  • Income from Continuing Operations reached 153700000.0 in Q4 2025 per NBIX's latest filing, down from 209500000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 209500000.0 in Q3 2025 to a low of 76600000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 65685000.0, with a median of 66750000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 1319.18% in 2022, then tumbled 651.08% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 7300000.0 in 2021, then surged by 1319.18% to 89000000.0 in 2022, then soared by 65.96% to 147700000.0 in 2023, then tumbled by 30.2% to 103100000.0 in 2024, then skyrocketed by 49.08% to 153700000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Income from Continuing Operations are 153700000.0 (Q4 2025), 209500000.0 (Q3 2025), and 107500000.0 (Q2 2025).